1.Analyzing heart period signal for fetus and pregnant woman in perinatal period.
Zhangyong LI ; Yonghong NIU ; Zhengxiang XIE ; Yuxia XU ; Yushu WEI
Journal of Biomedical Engineering 2003;20(3):507-510
Analyzing the digital characteristics (chaotic and spectral features) of fetal and pregnant woman's heart period signal (HPS) can assess the autonomic nervous system function. Extracting and analyzing HPS of fetal and pregnant woman in perinatal period were realized by using the method of visual programming. The subjects were in supine position. Electrocardiography-signal (ECS) from the leads placed at symphysis pubic bone to inferior border of abdominal wall was acquired. ECS was preprocessed by wavelet filter. The sophisticated technique developed by our laboratory was used to analyze the digital characteristics of HPS. The system could be used to assess fetal and pregnant woman's autonomic nervous system function, furthermore, sympathetic and parasympathetic nervous function could be evaluated respectively and quantificationally. The system also could be used to prognosticate fetal distress. The digital characteristics of fetal and other age groups' HPS, which vary with age, suggest the physiological process of development, mature and senility of autonomic nervous system; based on it, we could find the way of anti-senility. Some digital parameters of fetal HPS stand between those of newborn and adult, which may imply that fetal autonomic nervous regulation is influenced by mother's nerve and endocrine system.
Adult
;
Autonomic Nervous System
;
embryology
;
physiology
;
Electrocardiography
;
Female
;
Fetal Heart
;
physiology
;
Heart
;
physiology
;
Humans
;
Parasympathetic Nervous System
;
physiology
;
Pregnancy
;
Signal Processing, Computer-Assisted
2.Efficacy of different dosing regimens of Conbercept in the treatment of pathological myopic choroidal neovascularization
Huabin ZHENG ; Yushu NIU ; Zhi ZHOU ; Chunxia ZHANG
International Eye Science 2024;24(6):990-993
AIM: To compare the efficacy of different dosing regimens of conbercept in the treatment of pathological myopic choroidal neovascularization(CNV).METHODS: Prospective clinical study. Totally 42 patients(42 eyes)who were diagnosed with pathological myopic CNV in our hospital from January 2019 to January 2022 were selected in the study. According to two different initial dosing regimens, the patients were divided into 1+pro re nata(PRN)group, with 20 patients(20 eyes), and 3+PRN group with 22 patients(22 eyes). The patients in the 1+PRN group were given one intravitreal injection and then given PRN, the patients in the 3+PRN group were given intravitreal injection once a month for 3 mo and then given PRN. Followed-up for 12 mo after initial treatment, the best corrected visual acuity(BCVA), central macular thickness(CMT), CNV area and injection times were compared between the two groups.RESULTS: The BCVA was improved, CMT was decreased, and CNV area was reduced at 1, 3, 6, and 12 mo after the initial treatment(P<0.01). However, there was no statistically significant difference in BCVA, CMT and CNV area between two groups(P>0.05). The average injection in the 1+PRN group was significantly less than that of the 3+PRN group [2(1, 3)times vs 3(3, 4)times, P<0.05], but the average reinjection in the 1+PRN group was more than that of the 3+PRN group [1(0, 2)times vs 0(0, 1)times, P<0.05].CONCLUSION: Two regimens were both safe and effective in the treatment of pathological myopic CNV by Conbercept, which can improve BCVA, decrease CMT, and reduce CNV area, with less total times of injection in the 1+PRN regimen, and less times of reinjection in the 3+PRN regimen.